These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Bewersdorf JP; Zeidan AM Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498 [TBL] [Abstract][Full Text] [Related]
4. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Stahl M; Zeidan AM Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851 [TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Garcia-Manero G; Chien KS; Montalban-Bravo G Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763 [TBL] [Abstract][Full Text] [Related]
6. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? Bewersdorf JP; Zeidan AM Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100 [TBL] [Abstract][Full Text] [Related]
8. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes. Hochman MJ; DeZern AE Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129 [TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies in low and high-risk MDS: What does the future have to offer? Scalzulli E; Pepe S; Colafigli G; Breccia M Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020 [TBL] [Abstract][Full Text] [Related]
11. Raising the bar for lower-risk myelodysplastic syndromes. Venugopal S; Sekeres MA Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589 [TBL] [Abstract][Full Text] [Related]
12. Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Madanat YF; Xie Z; Zeidan AM Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919 [TBL] [Abstract][Full Text] [Related]
13. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. DeZern AE; Malcovati L; Ebert BL Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654 [TBL] [Abstract][Full Text] [Related]
15. Biology of the bone marrow microenvironment and myelodysplastic syndromes. Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353 [TBL] [Abstract][Full Text] [Related]
16. The genetic and molecular pathogenesis of myelodysplastic syndromes. Shallis RM; Ahmad R; Zeidan AM Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289 [TBL] [Abstract][Full Text] [Related]
17. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. Brunner AM; Steensma DP Clin Adv Hematol Oncol; 2018 Jan; 16(1):56-66. PubMed ID: 29741506 [TBL] [Abstract][Full Text] [Related]
19. How we manage adults with myelodysplastic syndrome. Fenaux P; Platzbecker U; Ades L Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568 [TBL] [Abstract][Full Text] [Related]